2018
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. Journal Of Clinical Oncology 2018, 36: 1619-1627. PMID: 29659329, PMCID: PMC5978470, DOI: 10.1200/jco.2017.76.5941.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisChemotherapy useBreast cancerEarly-stage breast cancerStudy designIncremental cost-effectiveness ratioODX recurrence scoreHigh-risk patientsLow-risk patientsRisk of biasCost-effectiveness ratioCost-effectiveness estimatesIndustry fundingDistant recurrenceIndustry-funded studiesClinical characteristicsTumor characteristicsRecurrence scoreChemotherapy decisionsScore groupClinical practiceSystematic reviewODXPatientsCancer
2016
Cost-effectiveness of Intensive Blood Pressure Management
Richman IB, Fairley M, Jørgensen ME, Schuler A, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of Intensive Blood Pressure Management. JAMA Cardiology 2016, 1: 872-879. PMID: 27627731, PMCID: PMC5892423, DOI: 10.1001/jamacardio.2016.3517.Peer-Reviewed Original ResearchConceptsIntensive blood pressure managementSystolic Blood Pressure Intervention TrialBlood pressure managementAdverse event ratesStandard managementPressure managementAdverse eventsPopulation-based observational dataSystolic blood pressure goalEvent ratesHigher adverse event ratesBlood pressure goalsSerious adverse eventsHigh-risk patientsHigh-risk adultsSystolic blood pressureNational Inpatient SampleTreatment of hypertensionCause-specific mortalityLifetime costsMarkov cohort modelCost-effectiveness analysisCardiovascular morbidityBlood pressureHeart failure